Very interesting results.
It's so hard to know how significant the role of the therapy was to getting these kids out of hospital, however, without a randomised control trial.
I know I always seem to come here as the skeptic, and I want to reiterate the results are interesting. But they mention in the article the kids were already improving prior to receiving the cells.
So it could've been the cells, it could've just been time. And saying it's one or the other is pure conjecture.
I guess one last thing to note is the conflicts of interest. But that's quite common in studies.
The above is probably why this didn't affect share price, if anyone was curious.
GLTAH
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-43
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.28 |
Change
-0.030(1.30%) |
Mkt cap ! $2.918B | |||
| Open | High | Low | Value | Volume |
| $2.32 | $2.39 | $2.24 | $13.10M | 5.680M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 44474 | $2.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.29 | 30176 | 3 |
View Market Depth
| Last trade - 16.17pm 22/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |